<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="111">
  <stage>Registered</stage>
  <submitdate>2/08/2005</submitdate>
  <approvaldate>9/08/2005</approvaldate>
  <actrnumber>ACTRN12605000101684</actrnumber>
  <trial_identification>
    <studytitle>Progressive Exercise for Anabolism in Kidney Disease</studytitle>
    <scientifictitle>A randomized phase III study to evaluate the effects of progressive resistance training in the treatment of muscle wasting to improve physical function and quality of life in end stage renal disease</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>End stage renal disease</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The experimental grroup will receive progressive Resistance Training for 24 weeks in addition to usual care.</interventions>
    <comparator>Control group will be wait-listed for 12 weeks receiving usual care only prior to receiving progressive resistance training + usual care for 12 weeks.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Skeletal muscle cross-sectional area and attenuation</outcome>
      <timepoint>Measured at baseline, week 12 and week 24</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>6-minute walk</outcome>
      <timepoint>Measured at baseline, week 12 and week 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Isometric muscular strength</outcome>
      <timepoint>Measured at baseline, week 12 and week 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Static balance</outcome>
      <timepoint>Measured at baseline, week 12 and week 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Geriatric Depression Scale (GDS)</outcome>
      <timepoint>Measured at baseline, week 12 and week 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of Life (SF-36)</outcome>
      <timepoint>Measured at baseline, week 12 and week 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Physical Activity Scale for the Elderly (PASE)</outcome>
      <timepoint>Measured at baseline, week 12 and week 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Haemotological markers</outcome>
      <timepoint>Measured at baseline, week 12 and week 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>C-reactive protein</outcome>
      <timepoint>Measured at baseline, week 12 and week 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dialysis Adequacy (Kt/V)</outcome>
      <timepoint>Measured at baseline, week 12 and week 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mini-nutritional assessment (MNA),</outcome>
      <timepoint>Measured at baseline, week 12 and week 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Protein Catabolic Rate</outcome>
      <timepoint>Measured at baseline, week 12 and week 24.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dietary Intake (Australian Food Frequency Questionnaire).</outcome>
      <timepoint>Measured at baseline, week 12 and week 24.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Stable hemodialysis patients with no contraindications to progressive resistance training.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>concealed opaque envelope. Assignment following baseline testing.</concealment>
    <sequence>computer-generated randomization list</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures>RCT</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>1/10/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>50</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Kidney Health Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Sydney</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Simbex Technologies</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Kidney Health Australia</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Sydney</sponsorname>
      <sponsoraddress />
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is an RCT to determine the effects of progressive resistance training during hemodialysis in patients with end-stage renal disease</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>SESAHS</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>RPAH</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>USYD</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Maria Fiatarone Singh</name>
      <address>University of Sydney
Cumberland Campus
East Street
Lidcombe NSW 2141</address>
      <phone>+61 2 93519755</phone>
      <fax>+61 2 93519204</fax>
      <email>m.singh@fhs.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Maria Fiatarone Singh</name>
      <address>University of Sydney
Cumberland Campus
PO Box 170 
Lidcombe NSW 1825</address>
      <phone>+61 2 93519755</phone>
      <fax>+61 2 93519204</fax>
      <email>m.singh@fhs.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>